コレラ・ワクチンの世界市場

コレラ・ワクチンの世界市場は2030年までに1億4,740万米ドルに達する見込み

2024年に9,110万米ドルと推定されるコレラ・ワクチンの世界市場は、2030年には1億4,740万米ドルに達し、分析期間2024-2030年のCAGRは8.4%で成長すると予測されます。本レポートで分析したセグメントの1つであるキルド経口O1およびO139ワクチンは、CAGR 10.1%を記録し、分析期間終了までに8,640万米ドルに達すると予測されます。Whole Cell v. Cholerae O1 with Recombinant B-Subunit Vaccineセグメントの成長率は、分析期間中CAGR 6.2%と推定されます。

米国市場は2,480万米ドルと推定される一方、中国はCAGR 13.3％で成長すると予測される

米国のコレラ・ワクチン市場は、2024年には2,480万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGR13.3%で推移し、2030年には予測市場規模3,240万米ドルに達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.1%と8.1%と予測されています。欧州では、ドイツがCAGR 5.6%で成長すると予測されています。

世界のコレラ・ワクチン市場- 主要動向と促進要因まとめ

なぜコレラ・ワクチンの需要が増加しているのか？

コレラ・ワクチンの需要が増加しているのは、コレラ発生の増加、流行地域における予防医療対策の必要性の高まり、公衆衛生の脅威としてのコレラの撲滅を目指した世界の取り組みが背景にあります。コレラは、開発途上諸国、特に衛生環境が不十分で清潔な水へのアクセスが限られている地域において、依然として大きな懸念となっています。都市化と気候変動が水系感染症の蔓延を助長する中、コレラ感染を予防する効果的なワクチンの需要が高まっています。政府、非政府組織、世界保健機関（WHO）やワクチン同盟（Gavi）などの国際保健機関は、大規模なコレラ・ワクチン接種プログラムに積極的に投資しています。集団予防接種への取り組み、ワクチンの緊急備蓄、ワクチン開発のための資金増加などが市場開拓をさらに後押ししています。さらに、高リスク地域への渡航が増加していることから、旅行者の間でコレラ・ワクチンの採用が増加しており、需要をさらに押し上げています。世界ヘルスへの取り組みが拡大し続ける中、コレラ・ワクチンへのニーズは引き続き高いです。

技術の進歩はどのようにコレラ・ワクチンを向上させているのでしょうか？

ワクチン開発、生産効率、送達メカニズムの進歩は、コレラ・ワクチンの入手しやすさと有効性を大幅に向上させています。最も注目すべき技術革新のひとつは、経口コレラ・ワクチンの開発であり、大量予防接種キャンペーンにおいて、より簡単な投与と幅広い適用範囲を実現しています。殺傷した全細胞ワクチンや弱毒化した生ワクチンのようなこれらのワクチンは、注射ワクチンに関連する物流上の課題を軽減しながら、長期にわたる免疫を提供します。もうひとつの大きな飛躍的進歩は、ワクチン製造における組み換えDNA技術や合成生物学の導入です。これらの技術革新により、より安定した、安価でスケーラブルなワクチンの製造が可能になり、コレラが最も蔓延している低所得地域でも利用できるようになりました。さらに、コールドチェーン・ロジスティクスと熱安定性製剤の改善により、インフラが限られた遠隔地でも、より優れたワクチン配布が可能になりつつあります。ワクチン技術が進化し続けるにつれて、コレラ予防接種プログラムの世界の範囲が拡大し、脆弱な人々の疾病負担が軽減されることが期待されます。

コレラ・ワクチン市場の成長を牽引する市場動向は？

予防ヘルスケアと疫病対策への注目の高まりは、コレラ・ワクチン市場を形成する主要動向の一つです。政府や国際機関は、流行後の治療のみに頼るのではなく、流行を予防するための積極的なワクチン接種キャンペーンを優先しています。このようなアプローチの転換により、備蓄ワクチンの需要が高まり、リスクの高い地域では先制的な予防接種の取り組みが行われています。市場成長に影響を与えるもう一つの重要な動向は、ワクチン研究と流通における官民パートナーシップの拡大です。製薬会社、研究機関、国際保健機関の連携により、コレラワクチン開発のイノベーションが推進され、十分なサービスを受けていない地域でのワクチンへのアクセスが改善されています。さらに、コレラを含む複数の細菌感染を予防する混合ワクチンの台頭は、費用対効果が高く効率的な予防接種戦略として注目を集めています。こうした動向が市場を形成し続ける中、コレラ・ワクチンは世界の公衆衛生活動の中心的なツールとなりつつあります。

コレラ・ワクチン市場の将来を形作る主な成長促進要因とは？

コレラ・ワクチン市場の成長は、予防接種プログラムへの投資の増加、コレラ予防に対する意識の高まり、ワクチン製造技術の進歩など、いくつかの要因によってもたらされます。主な成長要因の1つは、コレラ流行地域を対象とした人道的・緊急対応イニシアチブの増加です。災害救援や難民保健プログラムに携わる組織は、コレラ・ワクチン接種を標準的な予防策として取り入れており、これが需要をさらに押し上げています。市場を形成するもう一つの重要な要因は、旅行関連のワクチン推奨の拡大です。仕事、観光、人道的任務のためにコレラの発生しやすい地域を訪れる人が増えるにつれ、渡航前のワクチン接種に対する需要が高まっています。さらに、有効性が改善され、免疫がより長く持続する次世代ワクチンの研究が進んでおり、さらなる普及が期待されています。コレラの制圧と撲滅に向けた世界の取り組みが継続される中、ワクチン市場は持続的な成長を遂げ、流行地域と高リスク地域の両方で健康上の成果が改善されるものと思われます。

セグメント

製品タイプ（キルド経口O1およびO139ワクチン,全細胞v.コレラ菌O1と組換えBサブユニットワクチン）;コレラ菌タイプ（デュコラル,バクスコラ,シャンコール,その他）;流通チャネル（病院薬局,小売薬局,その他流通チャネル）

調査対象企業の例

• Astellas Pharma Inc.
• Bavarian Nordic
• Bharat Biotech Ltd.
• Celldex Therapeutics
• Emergent BioSolutions Inc.
• EuBiologics Co., Ltd.
• GlaxoSmithKline plc（GSK）
• Hilleman Laboratories
• Incepta Vaccine Ltd.
• International Vaccine Institute
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• PaxVax, Inc.
• Pfizer Inc.
• Sanofi S.A.
• Shanghai United Cell Biotechnology Co., Ltd.
• Shantha Biotechnics Limited
• Takeda Pharmaceutical Company Limited
• Vabiotech
• Valneva SE

AIインテグレーション

私たちは、検証された専門家のコンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMをクエリする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋地域
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Cholera Vaccines Market to Reach US$147.4 Million by 2030

The global market for Cholera Vaccines estimated at US$91.1 Million in the year 2024, is expected to reach US$147.4 Million by 2030, growing at a CAGR of 8.4% over the analysis period 2024-2030. Killed Oral O1 and O139 Vaccine, one of the segments analyzed in the report, is expected to record a 10.1% CAGR and reach US$86.4 Million by the end of the analysis period. Growth in the Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine segment is estimated at 6.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$24.8 Million While China is Forecast to Grow at 13.3% CAGR

The Cholera Vaccines market in the U.S. is estimated at US$24.8 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$32.4 Million by the year 2030 trailing a CAGR of 13.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 8.1% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.6% CAGR.

Global Cholera Vaccines Market - Key Trends & Drivers Summarized

Why Is the Demand for Cholera Vaccines Increasing?

The demand for cholera vaccines is increasing due to the rising incidence of cholera outbreaks, the growing need for preventive healthcare measures in endemic regions, and global initiatives aimed at eliminating cholera as a public health threat. Cholera remains a major concern in developing countries, particularly in areas with inadequate sanitation and limited access to clean water. As urbanization and climate change contribute to the spread of waterborne diseases, the demand for effective vaccines to prevent cholera infections has intensified. Governments, non-governmental organizations, and global health agencies such as the World Health Organization and Gavi, the Vaccine Alliance, are actively investing in large-scale cholera vaccination programs. Mass immunization efforts, emergency stockpiling of vaccines, and increased funding for vaccine development have further driven market growth. Additionally, rising travel to high-risk areas has led to an increase in the adoption of cholera vaccines among travelers, further boosting demand. As global health initiatives continue to expand, the need for cholera vaccines remains strong.

How Are Technological Advancements Improving Cholera Vaccines?

Advancements in vaccine development, production efficiency, and delivery mechanisms are significantly improving the accessibility and effectiveness of cholera vaccines. One of the most notable innovations is the development of oral cholera vaccines, which provide easier administration and broader coverage in mass immunization campaigns. These vaccines, such as those using killed whole-cell or live-attenuated strains, offer long-lasting immunity while reducing logistical challenges associated with injectable vaccines. Another major breakthrough is the implementation of recombinant DNA technology and synthetic biology in vaccine manufacturing. These innovations allow for the production of more stable, affordable, and scalable vaccines, making them accessible to low-income regions where cholera is most prevalent. Additionally, improvements in cold chain logistics and heat-stable formulations are enabling better vaccine distribution in remote areas with limited infrastructure. As vaccine technology continues to evolve, the global reach of cholera immunization programs is expected to expand, reducing the disease burden in vulnerable populations.

Which Market Trends Are Driving Growth in the Cholera Vaccines Market?

The increasing focus on preventive healthcare and epidemic preparedness is one of the key trends shaping the cholera vaccines market. Governments and international organizations are prioritizing proactive vaccination campaigns to prevent outbreaks rather than relying solely on post-epidemic treatment. This shift in approach has led to greater demand for stockpiled vaccines and preemptive immunization efforts in high-risk regions. Another significant trend influencing market growth is the expansion of public-private partnerships in vaccine research and distribution. Collaborations between pharmaceutical companies, research institutions, and global health organizations are driving innovations in cholera vaccine development and improving access to vaccines in underserved areas. Additionally, the rise of combination vaccines that protect against multiple bacterial infections, including cholera, is gaining attention as a cost-effective and efficient immunization strategy. As these trends continue to shape the market, cholera vaccines are becoming a central tool in global public health efforts.

What Are the Key Growth Drivers Shaping the Future of the Cholera Vaccines Market?

The growth of the cholera vaccines market is driven by several factors, including increasing investments in immunization programs, rising awareness of cholera prevention, and advancements in vaccine production technology. One of the primary growth drivers is the growing number of humanitarian and emergency response initiatives targeting cholera-endemic regions. Organizations involved in disaster relief and refugee health programs are incorporating cholera vaccination as a standard preventive measure, further driving demand. Another crucial factor shaping the market is the expansion of travel-related vaccine recommendations. As more people travel to cholera-prone areas for work, tourism, or humanitarian missions, the demand for pre-travel vaccination has increased. Additionally, ongoing research into next-generation cholera vaccines with improved efficacy and longer-lasting immunity is expected to drive further adoption. With continued global efforts to control and eliminate cholera, the market for vaccines is set to experience sustained growth, improving health outcomes in both endemic and high-risk regions.

SCOPE OF STUDY:

The report analyzes the Cholera Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Product Type (Killed Oral O1 and O139 Vaccine, Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine); Cholera Type (Dukoral, Vaxchora, Shanchol, Other Types); Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -

• Astellas Pharma Inc.
• Bavarian Nordic
• Bharat Biotech Ltd.
• Celldex Therapeutics
• Emergent BioSolutions Inc.
• EuBiologics Co., Ltd.
• GlaxoSmithKline plc (GSK)
• Hilleman Laboratories
• Incepta Vaccine Ltd.
• International Vaccine Institute
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• PaxVax, Inc.
• Pfizer Inc.
• Sanofi S.A.
• Shanghai United Cell Biotechnology Co., Ltd.
• Shantha Biotechnics Limited
• Takeda Pharmaceutical Company Limited
• Vabiotech
• Valneva SE

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • Tariff Impact on Global Supply Chain Patterns
  • Cholera Vaccines - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Rising Global Incidence of Cholera Outbreaks Throws the Spotlight on Vaccine Deployment and Access
  • Growing Emphasis on Public Health Preparedness Expands Addressable Market for Cholera Immunization Programs
  • Increased Demand in Endemic and Humanitarian Crisis Regions Drives Accelerated Vaccine Distribution Efforts
  • Advancements in Oral Cholera Vaccine (OCV) Formulations Propel Market Growth Through Improved Compliance
  • Global Health Initiatives and WHO Endorsements Strengthen the Business Case for Mass Vaccination Campaigns
  • Surge in International Funding and Gavi Support Fuels Vaccine Procurement and Cold Chain Infrastructure Development
  • Government-Driven Immunization Programs in Low-Income Countries Generate High-Volume Demand for Cost-Effective Vaccines
  • Technological Innovations in Vaccine Manufacturing and Storage Enhance Product Stability and Scalability
  • Integration of Cholera Vaccines into Routine Immunization Schedules Drives Sustainable Demand in High-Risk Regions
  • Urbanization, Climate Change, and Water Contamination Trends Increase Vulnerability and Drive Vaccine Adoption
  • Rising Traveler Awareness and Pre-Travel Vaccination Requirements Fuel Demand in Non-Endemic Markets
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Cholera Vaccines Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Cholera Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Cholera Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 4: World 15-Year Perspective for Cholera Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for Killed Oral O1 and O139 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for Killed Oral O1 and O139 Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 7: World 15-Year Perspective for Killed Oral O1 and O139 Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 10: World 15-Year Perspective for Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Dukoral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Dukoral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 13: World 15-Year Perspective for Dukoral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Vaxchora by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Vaxchora by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 16: World 15-Year Perspective for Vaxchora by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Shanchol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Shanchol by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 19: World 15-Year Perspective for Shanchol by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 22: World 15-Year Perspective for Other Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 25: World 15-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 28: World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 31: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 34: USA 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 37: USA 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 40: USA 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 43: Canada 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 46: Canada 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 49: Canada 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• JAPAN
  • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 52: Japan 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 55: Japan 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 58: Japan 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• CHINA
  • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 61: China 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 64: China 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 67: China 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• EUROPE
  • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Cholera Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Cholera Vaccines by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 70: Europe 15-Year Perspective for Cholera Vaccines by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 73: Europe 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 76: Europe 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 79: Europe 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• FRANCE
  • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 82: France 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 85: France 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 88: France 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• GERMANY
  • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 91: Germany 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 94: Germany 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 97: Germany 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 100: Italy 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 103: Italy 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 106: Italy 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• UNITED KINGDOM
  • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 109: UK 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 112: UK 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 115: UK 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 118: Spain 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 121: Spain 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 124: Spain 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 127: Russia 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 130: Russia 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 133: Russia 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• ASIA-PACIFIC
  • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Cholera Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Cholera Vaccines by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 15-Year Perspective for Cholera Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• AUSTRALIA
  • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 157: Australia 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 160: Australia 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 163: Australia 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• INDIA
  • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 166: India 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 169: India 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 172: India 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 175: South Korea 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 178: South Korea 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 181: South Korea 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• LATIN AMERICA
  • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Cholera Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Cholera Vaccines by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 193: Latin America 15-Year Perspective for Cholera Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 196: Latin America 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 199: Latin America 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 202: Latin America 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 205: Argentina 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 208: Argentina 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 211: Argentina 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 214: Brazil 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 217: Brazil 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 220: Brazil 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 223: Mexico 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 226: Mexico 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 229: Mexico 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• MIDDLE EAST
  • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Cholera Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Cholera Vaccines by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 241: Middle East 15-Year Perspective for Cholera Vaccines by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 244: Middle East 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 247: Middle East 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 250: Middle East 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 253: Iran 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 256: Iran 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 259: Iran 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 262: Israel 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 265: Israel 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 268: Israel 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 280: UAE 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 283: UAE 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 286: UAE 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030
• AFRICA
  • Cholera Vaccines Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Cholera Vaccines by Product Type - Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 298: Africa 15-Year Perspective for Cholera Vaccines by Product Type - Percentage Breakdown of Value Sales for Killed Oral O1 and O139 Vaccine and Whole Cell v. Cholerae O1 with Recombinant B- Subunit Vaccine for the Years 2015, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Cholera Vaccines by Cholera Type - Dukoral, Vaxchora, Shanchol and Other Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 301: Africa 15-Year Perspective for Cholera Vaccines by Cholera Type - Percentage Breakdown of Value Sales for Dukoral, Vaxchora, Shanchol and Other Types for the Years 2015, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Cholera Vaccines by Distribution Channel - Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
  • TABLE 304: Africa 15-Year Perspective for Cholera Vaccines by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION